Cancer Prevention and Control Planning Grant Program (Clinical Trials Optional) R34 PAR-22-173 U34 PAR-22-174

Brandy Heckman-Stoddard, PhD, MPH Chief, Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention Susan M. Czajkowski, PhD Chief, Health Behaviors Research Branch, Division of Cancer Control and Population Sciences Ann Geiger, PhD, MPH

Scientific Director of Cancer Care Delivery Research, NCI Community Oncology Research Program




August 8, 2022

Session Agenda

- 1. Planning Grants for Cancer Prevention and Control Clinical Trials (R34 and U34 Clinical Trials Optional)
 - Brandy Heckman-Stoddard, PhD, MPH
- 2. Planning Grants for Behavioral Interventions in Cancer Prevention and Control
 - Susan Czajkowski, PhD
- 3. Q&A
 - Brandy Heckman-Stoddard, PhD, MPH
 - Susan Czajkowski, PhD
 - Ann Geiger, PhD, MPH

Prior Structure for Funding for Clinical Trials



What is a R34 or U34?

From OER definition of grant mechanisms (R34 and U34):

For clinical trials, the planning grant is designed to:

- permit early peer review of the rationale and concept for the proposed clinical trial;
- support development of essential elements of a clinical trial
- lead to an application for support of a full-scale trial, based on elements developed under the planning period

History of R34 and U34 at NIH

- R34 currently used by NIDA, NIDDK, NIAAA, NIMH, NIAID, NEI, NINDS, NCATS, and NHLBI
- U34 currently used by NCATS and NIDDK
- Not previously used by NCI

Example U34- U34DK124174-01(Sachin Wani)

Background: Endoscopic eradication therapy (EET) is the standard of care for patients with Barrett's Esophagus (BE) and high-grade dysplasia (HGD) or mucosal esophageal adenocarcinoma.

Primary aim: Determine if BE patients with low-grade dysplasia (LGD) benefit from EET.

Planning aims:

- Compare the two approaches using the primary endpoint of neoplastic progression rate (progression to HGD or mucosal or invasive EAC).
- Compare defined patient-centered outcomes such as health-related quality of life between the two treatment groups.
- Compare the performance of molecular (TissueCypher and p53 immunohistochemistry) and imaging (wide-area transepithelial sampling – WATS) biomarkers to conventional histologic assessment of dysplasia via forceps biopsy to improve risk-stratification in BE with LGD patients

Why planning grants are needed for DCP and DCCPS late phase trials?

Cancer Prevention and Control trials :

- Often do not have pharmaceutical or industry support
- Involve multi-disciplinary teams that may not have worked together previously including primary care physicians and other specialists.
- Often challenging statistical issues about best study design, control group, endpoint, etc.
- Feasibility of recruitment and acceptance of randomization
- Design better trials that are more successful

Purpose of Planning Grant

- Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors.
- Yield information that is both scientifically necessary and also sufficient to permit final decisions about the design or conduct of the large Phase II or beyond clinical trial.
- Application must include a summary of the future planned clinical trial
- Enhance rigor while saving time and cost to ensuring future trial success.
- Planning grant is not a prerequisite for an R01 funding clinical trial or a large trial through a network.

Examples of research needs include but are not limited to the following:

- Identify the appropriate control or comparison group to use in the subsequent clinical trial.
- Standardize and evaluate feasibility of the intervention or outcome across multiple sites.
- Feasibility and plan for development of a placebo
- Standardize and validate survey instruments.
- Standardize and test effectiveness of training tools.
- Adapt and test an intervention or outcome instrument for a population that differs culturally from the population for which the instrument was originally designed.
- Modeling data to support trial assumptions in the study design.
- Statistical planning and design
- Perform studies to refine the appropriate study population, intervention, outcome, and/ or study endpoint.

Due Dates

Application Due Dates			Review and Award Cycles		
New	Renewal / Resubmission / Revision (as allowed)	AIDS	Scientific Merit Review	Advisory Council Review	Earliest Start Date
October 25, 2022	October 25, 2022	January 07, 2023 *	March 2023	May 2023	July 2023
February 24, 2023	February 24, 2023	May 07, 2023 *	July 2023	October 2023	December 2023
June 26, 2023	June 26, 2023	September 07, 2023 *	November 2023	January 2024	April 2024
October 25, 2023	October 25, 2023	January 07, 2024 *	March 2024	May 2024	July 2024
February 27, 2024	February 27, 2024	May 07, 2024 *	July 2024	October 2024	December 2024
June 25, 2024	June 25, 2024	September 07, 2024 *	November 2024	January 2025	April 2025
October 25, 2024	October 25, 2024	January 07, 2025 *	March 2025	May 2025	July 2025
February 25, 2025	February 25, 2025	May 07, 2025 *	July 2025	October 2025	December 2025
June 25, 2025	June 25, 2025	September 07, 2025 *	November 2025	January 2026	April 2026

NIH standard due dates marked with an asterisk.

Funding Period and Budget

- Planning grant support can be requested for a maximum of 3 years.
- Application budgets are limited to \$225,000 per year and \$450,000 in direct costs over the 3year project period without a clinical trial.
- Applications that include a pilot/feasibility clinical trial are limited to \$225,000 per year and \$600,000 in direct costs over the 3-year project period.
- There are no set aside funds.

Required Attachments

- Milestone Plan
- Stakeholder Engagement Plan
- Future Clinical Trial Description

Milestone Plan

- The filename "Milestone Plan.pdf" should be used and the attachment should not exceed 2 pages.
- Detailed information and timelines for completing all necessary planning activities. Milestones should be easily measurable and realistic.
- These milestones will be negotiated at the time of the award, as appropriate.
- The Milestone plan is a separate document from the Study Timeline.

Stakeholder Engagement Plan

- The Filename "Stakeholder Engagement Plan.pdf" should be used and the attachment should not exceed 2 pages.
- The application must describe multi-level stakeholder engagement activities already conducted and how these activities influenced the development of the protocol or proposed study conduct, including recruitment.
- The application should also describe any stakeholder engagement efforts planned during the planning period and how these activities will be used.

Future Clinical Trial Description

- The filename "Future Clinical Trial Description.pdf" should be used and the attachment may not exceed 3 pages.
- Provide a description to the extent known of the *future* clinical trial to provide context for information sought in the Planning award.
- The summary should not describe the pilot/feasibility trial that may be conducted during the Planning period of award.

Letters of Support

- Provide all appropriate letters of support, including any letters necessary to demonstrate the support of consortium/site participants, cores, laboratories, pharmacies, and other collaborators, including cost-sharing by NIH resources, in the case of intramural collaborators.
- If co-funding or in-kind support is planned from any source (non-NIH sources or NIH sources), letter(s) outlining details of the commitment (e.g. type, amount, and source of support), signed by a business official on organization letterhead, must be included.
- Letters of support should also be provided from individuals or organizations that have been or will be involved in stakeholder engagement efforts.


PHS Human Subjects and Clinical Trials Information

- Description of the feasibility/ pilot study that will be conducted as part of the planning award
- 2.5 Recruitment and Retention Plan
- 2.7 Study Timeline (Directly relates to the pilot/ feasibility study vs. the milestone plan which captures the all the work in the planning grant.)
- 4.3 Statistical Design and Power

Comparing and contrasting the R34 vs U34

Investigator-initiated R34	Network facilitated U34
Preparatory to Phase II/III, but specific pathway undetermined	Preparatory to large Phase II/III within specified network
"Necessary and sufficient"; No scientific requirements	Required activities – network engagement, adhere to existing rules for concept and protocol review
R	U
1-3 Years	1-3 years
Followup study potentially funded through R01	Followup study potentially funded through CP- CTNet, ULACNet, NCORP, etc.

Funding through the intervention vs. biomarker pipeline



Using an NCI Network to Conduct Research

- Research must be conducted via Network sponsorship
- Researcher contacts Research Base, Partnership Center, Lead Academic Organization to secure sponsorship
- Lead network site must notify NCI Program Director if plan to submit federally funded grant application (R01, U34, etc.)
 - Study chair, Lead network site PI, and NCI PD discuss aims, population, rationale/feasibility, timeline/budget considerations
 - Determine if within scope of program and there is no overlap with other projects in the pipeline or active

NCORP Symptom Management Example #1 Funded R34 - R34HL146927 NCORP Trial EAQ191 (Bonnie Ky)

Background: In non-cancer populations, SPRINT demonstrated that intensive systolic blood pressure (SBP) lowering to a target <120mmHg substantially reduces the rate of cardiovascular (CV) events and all-cause mortality.

Primary aim: tolerability of intensive SBP control that limited application of guidelines for aggressive SBP targets in clinical practice for oncology patients.

Planning Grant Activities

- Perform a retrospective analysis to define the distributions of SBP, CV risk scores, incidence of CV events, and all-cause mortality rates in cancer patients
- Perform a 60-patient prospective pilot study using a site-based cluster randomization design amongst 4 ECOG-ACRIN sites comparing 'Intensive SBP Control' with 'Usual Care.' This will be facilitated by a centralized BP Advisory Core, and will inform the SBP trajectories, safety and tolerability of Intensive SBP control, and participant and site burden.

NCORP Symptom Management Example #2

- Primary aim: To compare the effect of prophylactic anti-HBV therapy versus upon indication anti-HBV therapy on time-to-adverse liver outcomes of liver failure or liver- related death in patients with chronic HBV infection (HBsAg+ and anti-HBc+) receiving anti-cancer therapy for solid tumors.
- Patient population: diagnosed with stage I-III solid tumor planning to receive systemic anticancer therapy

- The prevalence of chronic HBV infection is reported to be 0.3%, and the prevalence of past HBV infection is 4.6% though these rates may be underreported
 - Conduct a survey within NCORP to understand the prevalence within the network
 - Conduct site and physician assessment of feasibility
- Develop a process to identify patients including developing a relationship with infectious disease/gastroenterologists currently treating this patient population
- Develop and test a recruitment plan

NCORP Cancer Care Delivery Research Example #1

Primary Aim: compare 8-week post-operative function among elderly patients between sites randomized to implement a toolkit to assess and manage frailty with or without implementation coaching, compared to usual care

Patient Eligibility: elderly patients requiring major surgery for cancer who are assessed as frail using a standard measure

Practice Setting: surgical practices that conduct a minimum number of major cancer surgeries

- Pilot procedures for data collection that require direct observation of surgeons and staff in clinical settings
- Assess how frailty assessment can be incorporated into existing clinical workflows
- Formally evaluate physician and practice interest and capacity for implementation activities, including toolkit development

NCORP Cancer Care Delivery Research Example #2


Primary Aim: compare the effectiveness of virtual learning collaborative versus technical assistance on uptake of an existing palliative care program

Patient Eligibility: diagnosed within the last 90 days with an advanced cancer

Practice Setting: medical oncology

- Determine feasibility and uptake of virtual nurse training program
- Assess time commitment and staffing considerations for practice participation in technical assistance and virtual learning collaborative
- Develop and evaluate Spanish version of existing program and outcome measures


Up to 50% of Cancers May Be Preventable through Health Behavior Change



NCI's Behavioral Intervention Priorities



NCI supports behavioral clinical trials that span multiple levels of analysis and all phases of the translational spectrum and cancer control continuum



https://cancercontrol.cancer.gov/brp/hbrb/strategy.html

26


Planning grants for behavioral intervention studies – relevant topics

- Behavioral research in cancer prevention and control: development and testing of interventions addressing risk behaviors such as: tobacco use, energy balance, or sun exposure; vaccine uptake; immune function; screening behavior; treatment adherence; biopsychosocial processes of cancer-related behavior; communication, decision science, environmental modifications and policy changes aimed at altering cancer-related health behaviors and/or preventing or improving cancer-related risks and outcomes.
- Healthcare delivery: single and multi-level interventions addressing the organization and/or delivery of cancer care (e.g., team-based care; novel use of electronic health records; new organizational mechanisms/staffing such as patient navigation; new models of specialized services such as palliative care or survivorship programs).
- Cancer survivorship: interventions addressing the physical, psychological, social, and financial burden of cancer and its treatment among survivors of cancer and their families (e.g., social functioning, caregiver adaptation).
- Implementation science: strategies to promote the adoption, implementation, and sustainability of evidence-based intervention into routine healthcare and public health settings or the deimplementation of ineffective interventions.

Comparing and contrasting the R34 vs U34

Investigator-initiated R34	Network facilitated U34
Preparatory to Phase II/III, but specific pathway undetermined	Preparatory to large Phase II/III within specified network
"Necessary and sufficient"; No scientific requirements	Required activities – network engagement, adhere to existing rules for concept and protocol review
R	U
1-3 Years	1-3 years
Followup study potentially funded through R01	Followup study potentially funded through CP- CTNet, ULACNet, NCORP, etc.

There are 2 phases on the behavioral intervention development & testing pipeline where a planning grant may be useful



Czajkowski, Powell et al., *Health Psychology* 2015; Powell, Freedland & Kaufmann, *Behavioral Clinical Trials for Chronic Diseases*, 2021

Examples of research needs relevant to behavioral clinical trials in cancer prevention and control

- Perform studies to refine the appropriate study population, intervention, outcome, and/or study endpoint.
- Collect information necessary to identify appropriate recruitment methods and estimate available populations, screening-to-enrollment yield, attrition rate, or response rate and ensure a diverse and adequate study population.
- Identify the appropriate control or comparison group to use in the subsequent clinical trial.
- Standardize the intervention or outcome across multiple sites.
- Test the feasibility of an outcome or intervention in the field &/or determine acceptability of the intervention to study participants.
- Determine whether adequate adherence to an intervention is achievable.
- Standardize and validate survey instruments.
- Statistical planning and design.

Perform studies to refine the appropriate study population, intervention, outcome, and/or endpoint

Example:

- A Phase III clinical trial is being planned to test a weight loss intervention on invasive disease-free survival in women with breast cancer
- Prior research has established the ability of an in-person intervention to achieve the desired degree of weight loss in this population

- Test whether a *telehealth* intervention using the same elements as the in-person intervention can achieve similar results in the same study population used in prior research
- Test whether a version of the in-person intervention that is adapted for use with a different population can achieve similar results as in the original study

Examples of research needs relevant to behavioral clinical trials in cancer prevention and control

- Perform studies to refine the appropriate study population, intervention, outcome, and/or study endpoint.
- Collect information necessary to identify appropriate recruitment methods and estimate available populations, screening-to-enrollment yield, attrition rate, or response rate and ensure a diverse and adequate study population.
- Identify the appropriate control or comparison group to use in the subsequent clinical trial.
- Standardize the intervention or outcome across multiple sites.
- Test the feasibility of an outcome or intervention in the field &/or determine acceptability of the intervention to study participants.
- Determine whether adequate adherence to an intervention is achievable.
- Standardize and validate survey instruments.
- Statistical planning and design.

Collect information necessary to identify appropriate recruitment methods, screening-to-enrollment yield, attrition rate, adherence, feasibility/acceptability

- Example:
 - A Phase III clinical trial is being planned to test a weight loss intervention on invasive disease-free survival in women with breast cancer
 - The large sample size needed requires the use of multiple recruitment sites to achieve adequate power for determining effects on the endpoint of interest

- Determine whether the specific sites being considered for the larger trial can achieve specified recruitment goals in timely fashion
- Determine the screening-to-enrollment yield for use in the larger planned study
- Determine retention rate, degree of adherence to the intervention, and feasibility/acceptability of the intervention to the population of interest

Scientific contacts:

Brandy Heckman-Stoddard, PhD, MPH Chief, Breast and Gynecologic Cancer Research Group Division of Cancer Prevention <u>brandy.heckman-stoddard@nih.gov</u>

Susan M. Czajkowski, PhD Chief, Health Behaviors Research Branch Division of Cancer Control and Population Sciences Susan.czajkowski@nih.gov

Ann Geiger, PhD, MPH Scientific Director of Cancer Care Delivery Research NCI Community Oncology Research Program <u>ann.geiger@nih.gov</u>

Thank you!

Questions?